» Articles » PMID: 31335937

Repurposing Antihypertensive Drugs for the Prevention of Alzheimer's Disease: a Mendelian Randomization Study

Overview
Journal Int J Epidemiol
Specialty Public Health
Date 2019 Jul 24
PMID 31335937
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Evidence concerning the potential repurposing of antihypertensives for Alzheimer's disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer's disease.

Methods: We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer's disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer's disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets.

Results: There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer's disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p = 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p = 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p = 0.45; SNPs = 153).

Conclusions: Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer's disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer's disease, they may not do so via systolic blood pressure.

Citing Articles

Summarizing attributable factors and evaluating risk of bias of Mendelian randomization studies for Alzheimer's dementia and cognitive status: a systematic review and meta-analysis.

Meng X, Li X, Cao M, Dong J, Wang H, Cao W Syst Rev. 2025; 14(1):61.

PMID: 40082927 PMC: 11905674. DOI: 10.1186/s13643-025-02792-5.


Mendelian randomization-based observational cohort study on drug targets: Impact of antihypertensive and lipid-lowering therapies on inflammatory cytokines.

Xin J, Xu Z, Zhang F, Sun Y, Wang X, Wu C Medicine (Baltimore). 2025; 104(10):e41771.

PMID: 40068040 PMC: 11903001. DOI: 10.1097/MD.0000000000041771.


Association of antihypertensive drug target genes with alzheimer's disease: a mendelian randomization study.

Zheng H, Chen C, Feng Y Alzheimers Res Ther. 2025; 17(1):18.

PMID: 39794838 PMC: 11720623. DOI: 10.1186/s13195-025-01671-4.


Systematic review of Mendelian randomization studies on antihypertensive drugs.

Fan B, Zhang J, Zhao J BMC Med. 2024; 22(1):547.

PMID: 39567981 PMC: 11580643. DOI: 10.1186/s12916-024-03760-x.


Causal relationship between antihypertensive drugs and Hashimoto's thyroiditis: a drug-target Mendelian randomization study.

Cui B, Chen A, Xu C, Mao C, Chen Y Front Endocrinol (Lausanne). 2024; 15:1419346.

PMID: 39435355 PMC: 11491371. DOI: 10.3389/fendo.2024.1419346.


References
1.
Burgess S, Butterworth A, Thompson S . Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013; 37(7):658-65. PMC: 4377079. DOI: 10.1002/gepi.21758. View

2.
Davey Smith G, Ebrahim S . Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004; 33(1):30-42. DOI: 10.1093/ije/dyh132. View

3.
Lawlor B, Segurado R, Kennelly S, Olde Rikkert M, Howard R, Pasquier F . Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med. 2018; 15(9):e1002660. PMC: 6152871. DOI: 10.1371/journal.pmed.1002660. View

4.
Yasar S, Xia J, Yao W, Furberg C, Xue Q, Mercado C . Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology. 2013; 81(10):896-903. PMC: 3885216. DOI: 10.1212/WNL.0b013e3182a35228. View

5.
Corbett A, Pickett J, Burns A, Corcoran J, Dunnett S, Edison P . Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov. 2012; 11(11):833-46. DOI: 10.1038/nrd3869. View